Resistance to Ibrutinib

Publication
Article
Special ReportsHematologic Malignancies
Volume 1
Issue 1

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

View more about the treatment of chronic lymphocytic leukemia > >

Articles in this issue
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
In the Pipeline: Potential New Treatments for AML
In the Pipeline: Potential New Treatments for AML
Epidemiology in B-Cell Malignancies
Epidemiology in B-Cell Malignancies
Pathogenesis of Follicular Lymphoma
Pathogenesis of Follicular Lymphoma
Resistance to Ibrutinib
Resistance to Ibrutinib
IPI-145 and ABT-199 for Lymphoid Malignancies
IPI-145 and ABT-199 for Lymphoid Malignancies
BCL-2 Inhibitor Combo May Offer Remissions in CLL
BCL-2 Inhibitor Combo May Offer Remissions in CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
Recent Videos
Related Content
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers

Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers

Targeted Oncology Staff
December 20th 2024
Article

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia

FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia

Jordyn Sava
December 19th 2024
Article

The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

The Promise of Metabolomics to Transform Breast Cancer Screening

The Promise of Metabolomics to Transform Breast Cancer Screening

Morgan Bayer
December 19th 2024
Article

One new frontier of cancer detection is emerging: metabolomics.

Read More

Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Targeted Oncology Staff
December 18th 2024
Article

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.

Read More